Collegium Pharmaceutical, Inc. Expands its Management Team to Support Continued Development of DETERx® Tamper-Resistant, Extended-Release Opioid Program  
7/9/2012 10:51:32 AM

CUMBERLAND, R.I.--(BUSINESS WIRE)--Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, is pleased to announce the addition of three key members to its management team. Ernest A. Kopecky, PhD, MBA has joined the Company and will lead the clinical development team as Vice President, Clinical Development and Head, Neuroscience Therapeutic Area. In addition, Kathleen Findlen has joined the Company as Director of Clinical Operations and Stephen Mayock will lead the analytical team as Director of Analytical Development and Quality Control.